Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$44.25
-1.4%		$36.06
$20.37
▼
$45.14
$3.47B0.87962,948 shs31,358 shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$81.21
+3.7%		$73.96
$1.16
▼
$14.10
$3.52B-0.12189,291 shs254,558 shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$11.04
+11.1%		$10.15
$6.35
▼
$12.49
$980.55M0.381.55 million shs1.52 million shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$27.54
-1.0%		$31.13
$23.05
▼
$42.21
$3.22B0.11.04 million shs121,640 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
+1.22%+9.28%+16.45%+38.27%+88.53%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
+3.74%+4.38%+6.03%+15.96%+38.61%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+0.10%+8.04%-8.89%+2.05%+60.32%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
+0.76%+1.50%-16.38%-24.54%+11.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$44.25
-1.4%		$36.06
$20.37
▼
$45.14
$3.47B0.87962,948 shs31,358 shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$81.21
+3.7%		$73.96
$1.16
▼
$14.10
$3.52B-0.12189,291 shs254,558 shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$11.04
+11.1%		$10.15
$6.35
▼
$12.49
$980.55M0.381.55 million shs1.52 million shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$27.54
-1.0%		$31.13
$23.05
▼
$42.21
$3.22B0.11.04 million shs121,640 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
+1.22%+9.28%+16.45%+38.27%+88.53%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
+3.74%+4.38%+6.03%+15.96%+38.61%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+0.10%+8.04%-8.89%+2.05%+60.32%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
+0.76%+1.50%-16.38%-24.54%+11.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.86
Moderate Buy$55.4623.60% Upside
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.69
Moderate Buy$25.46156.15% Upside
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.93
Moderate Buy$49.3377.27% Upside

Current Analyst Ratings Breakdown

Latest KURA, GMTX, CLDX, and NAMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$40.00 ➝ $46.00
8/7/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$48.00 ➝ $53.00
8/6/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$51.00 ➝ $50.00
7/29/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$48.00 ➝ $72.00
7/28/2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$36.00
7/22/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$54.00 ➝ $48.00
7/22/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$44.00 ➝ $40.00
7/22/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$67.00 ➝ $61.00
7/22/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$62.00 ➝ $60.00
7/20/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$58.00
7/20/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$1.54M2,288.08N/AN/A$9.10 per share4.93
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$67.48M13.08N/AN/A$2.00 per share4.97
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$7.12M456.88N/AN/A$5.40 per share5.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$258.76M-$4.35N/AN/AN/AN/A-52.35%-47.61%N/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$278.67M-$3.35N/AN/AN/A-411.19%-141.95%-43.28%N/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$203.82M-$2.16N/AN/AN/A-3,644.21%-34.81%-31.50%N/A

Latest KURA, GMTX, CLDX, and NAMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.8773-$0.77+$0.1073-$0.77$20.16 million$20.87 million
8/6/2026Q2 2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$1.06-$0.94+$0.12-$0.94$0.74 million$0.02 million
8/5/2026Q2 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.4819-$0.52-$0.0381-$0.52$2.83 million$3.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
11.82
11.82
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.09
6.15
6.14
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
9.03
9.03

Institutional Ownership

CompanyInstitutional Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%

Insider Ownership

CompanyInsider Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
5.20%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
12.90%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
7.60%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
12.74%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
15078.53 million74.45 millionOptionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
13088.77 million82.03 millionOptionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
4116.90 million102.01 millionOptionable

Recent News About These Companies

HC Wainwright Brokers Reduce Earnings Estimates for NAMS
August 10 at 1:12 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951160
HC Wainwright Issues Pessimistic Outlook for NAMS Earnings
August 10 at 1:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-pessimistic-outlook-for-nams-earnings-2026-08-10/
Royal Bank Of Canada Cuts NewAmsterdam Pharma (NASDAQ:NAMS) Price Target to $50.00
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30950562
What is HC Wainwright's Forecast for NAMS FY2027 Earnings?
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30949481
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript
August 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931177-newamsterdam-pharma-company-n-v-nams-analyst-investor-day-transcript
Piper Sandler Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
August 8, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NAMS/pressreleases/3664690/piper-sandler-keeps-their-buy-rating-on-newamsterdam-pharma-company-nams/
BMO Capital Remains a Buy on NewAmsterdam Pharma Company (NAMS)
August 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3717167/bmo-capital-remains-a-buy-on-newamsterdam-pharma-company-nams/
Equities Analysts Offer Predictions for NAMS FY2027 Earnings
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/equities-analysts-offer-predictions-for-nams-fy2027-earnings-2026-08-07/
NewAmsterdam Pharma (NASDAQ:NAMS) Price Target Cut to $50.00 by Analysts at Royal Bank Of Canada
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/newamsterdam-pharma-nasdaqnams-price-target-cut-to-5000-by-analysts-at-royal-bank-of-canada-2026-08-06/
NewAmsterdam Pharma Company NV (NAMS) reports Q2 loss, lags revenue estimates
August 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/newamsterdam-pharma-company-nv-nams-reports-q2-loss-lags-revenue-estimates/ar-AA29sOJI
NewAmsterdam Pharma (NASDAQ:NAMS) Announces Quarterly Earnings Results
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/newamsterdam-pharma-nasdaqnams-announces-quarterly-earnings-results-2026-08-05/
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day - Slideshow
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931057-newamsterdam-pharma-company-n-v-nams-analyst-investor-day-slideshow
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/newamsterdam-pharma-maps-obicetrapib-strategy-as-prevail-interim-nears-2026-08-05/
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
August 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2968634/newamsterdam-pharma-company-n-v-nams-reports-q2-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2968634
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339184/0/en/newamsterdam-pharma-provides-corporate-update-and-reports-second-quarter-financial-results.html
RBC Capital Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)
August 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NAMS/pressreleases/3074103/rbc-capital-sticks-to-its-buy-rating-for-newamsterdam-pharma-company-nams/
Janus Henderson Group PLC Sells 82,739 Shares of NewAmsterdam Pharma Company N.V. $NAMS
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-janus-henderson-group-plc-sells-82739-shares-of-newamsterdam-pharma-company-nv-nams-2026-08-02/
NewAmsterdam Pharma Company N.V. $NAMS Stake Boosted by Stempoint Capital LP
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-newamsterdam-pharma-company-nv-nams-stake-boosted-by-stempoint-capital-lp-2026-07-30/
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
July 29, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/newamsterdam-pharma-to-host-investor-day-on-august-5-2026-1036377896
NewAmsterdam Pharma (NAMS) Projected to Announce Earnings on Wednesday
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/newamsterdam-pharma-nams-projected-to-announce-earnings-on-wednesday-2026-07-29/
Louise Frederika Kooij Sells 105,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/louise-frederika-kooij-sells-105000-shares-of-newamsterdam-pharma-nasdaqnams-stock-2026-07-28/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
Aerial view of a nuclear power plant with a cooling tower emitting steam, situated near a river at sunset.
3 Nuclear Stocks for Investors Willing to Wait Out the Dip
By Bridget Bennett | July 20, 2026
Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$44.25 -0.62 (-1.38%)
As of 10:13 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$81.21 +2.93 (+3.74%)
As of 08/11/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$11.04 +1.10 (+11.09%)
As of 10:14 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$27.54 -0.29 (-1.04%)
As of 10:13 AM Eastern
This is a fair market value price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas